These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30487231)

  • 41. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection.
    Pandey P; Zhao C; Liu B
    Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inclisiran in dyslipidemia.
    Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
    Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
    Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
    Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
    Wright RS; Koenig W; Landmesser U; Leiter LA; Raal FJ; Schwartz GG; Lesogor A; Maheux P; Stratz C; Zang X; Ray KK
    J Am Coll Cardiol; 2023 Dec; 82(24):2251-2261. PubMed ID: 38057066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
    Miname MH; Rocha VZ; Santos RD
    Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inclisiran: How Widely and When Should We Use It?
    Pirillo A; Catapano AL
    Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
    Rogula S; Błażejowska E; Gąsecka A; Szarpak Ł; Jaguszewski MJ; Mazurek T; Filipiak KJ
    J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First clinical experiences with inclisiran in a real-world setting.
    Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
    J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
    Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.
    Koenig W; Conde LG; Landmesser U; Leiter LA; Ray KK; Schwartz GG; Wright RS; Han J; Raal FJ
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):493-503. PubMed ID: 36550348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plain language summary of results from ORION-10 and ORION-11: two studies to learn how well inclisiran works in people with high cholesterol.
    Ray KK; Wright RS
    Future Cardiol; 2023 Mar; 19(4):175-184. PubMed ID: 37282500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.